New Zealand independent advisers
2026 to date · Independent adviser reports on deals announced to 10 Nov 2026 · 2 deals · NZ$360m disclosed
Columns
Every deal that counts towards this table, with the firms credited on it. Tick deals to leave them out of the ranking or to rank only those deals; the page then says the ranking is a custom view.
| Advisers | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2026 | Rekover Therapeutics | Tenmile | Invex Therapeutics | Acquisition | – | Announced | Biotech and pharmaceuticals | Moore Australia (buy-side) | Invex Therapeutics acquisition of Rekover Therapeutics | |
| Jan 2026 | Rakon | – | Bourns | Takeover | 360.0 | Completed | – | Calibre Partners (sell-side)Simmons Corporate Finance (buy-side) | Bourns acquisition of Rakon |
1 deal has no disclosed value. 2025 YTD rank is the firm's place in the same period a year earlier, under the same filters. Methodology